|Bid||11.40 x 4000|
|Ask||11.88 x 45100|
|Day's range||11.51 - 11.93|
|52-week range||9.66 - 15.92|
|Beta (5Y monthly)||1.30|
|PE ratio (TTM)||83.67|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||0.48 (4.11%)|
|Ex-dividend date||23 May 2022|
|1y target est||16.78|
Viatris Inc. and Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced today that Abevmy® (bevacizumab) is now available in Canada. Abevmy, co-developed by Viatris and Biocon Biologics, is a biosimilar to Roche's Avastin® (bevacizumab) and has been approved by Health Canada across four oncology indications.
Investors can look at the current market decline in one of two ways. Investors with long-term mindsets can find plenty of attractive opportunities in today's market. Viatris (NASDAQ: VTRS) appears to be a textbook value stock.
Here's why they chose BioNTech (NASDAQ: BNTX), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS). David Jagielski (BioNTech): Often investors discount a stock that may seem like it is punching above its weight class, on the assumption that it may struggle down the road. BioNTech's forward price-to-earnings multiple of around 3.8 certainly suggests that investors are perhaps not taking the growth stock seriously.